Imatinib mesylate is considered standard of care for firstline treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n ¼ 553) or interferon-a (IFN) plus cytarabine (n ¼ 553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC). The toxicity profile was unchanged. The cumulative best complete cytogenetic response (CCyR) rate was 82%; 63% of all patients randomized to receive imatinib and still on study treatment showed CCyR at last assessment. The estimated event-free survival at 6 years was 83%, and the estimated rate of freedom from progression to AP and BC was 93%. The estimated overall survival was 88%--or 95% when only CMLrelated deaths were considered. This 6-year update of IRIS underscores the efficacy and safety of imatinib as first-line therapy for patients with CML.
Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a chromosomal rearrangement of the long arms of chromosomes 9 and 22, forming the Philadelphia (Ph) chromosome. 1 This leads to the formation of a novel fusion gene, BCR-ABL, which encodes a constitutively active protein tyrosine kinase.
1 BCR-ABL has been shown to contribute to growth factor independence, increased proliferation, genetic instability and suppression of apoptosis in leukemia cells. [2] [3] [4] [5] [6] Imatinib mesylate (Glivec/Gleevec; formerly STI571; Novartis Pharmaceuticals, East Hanover, NJ, USA) blocks the ATP-binding site of BCR-ABL, 7 thereby inhibiting BCR-ABL tyrosine kinase activity and impeding downstream signaling. 8 After phase I and II studies established the safety of imatinib and demonstrated its ability to induce high hematologic response and cytogenetic response (CyR) rates in patients with CML, [9] [10] [11] [12] [13] [14] [15] a randomized trial, the International Randomized Study of Interferon vs STI571 (IRIS) was initiated to compare imatinib with the previous standard of care for chronic phase CML (CML-CP), interferon-a (IFN) plus cytarabine in newly diagnosed patients with CML-CP. The initial results of the IRIS trial, which established imatinib as the standard first-line therapy for patients with newly diagnosed CML-CP, have been reported previously. 16 Owing to the large proportion of patients in the IFN plus cytarabine arm who crossed over to the imatinib arm of the trial, long-term follow-up analyses have focused on patients initially randomized to receive imatinib therapy. After 5 years of followup, high survival rates were demonstrated for imatinib-treated patients, with event-free survival (EFS) rates without progression to accelerated phase (AP) or blast crisis (BC), and overall survival (OS) rates of 83, 93 and 89%, respectively. 17 This study focuses on the 6-year efficacy follow-up of the imatinib arm of the IRIS trial.
Materials and methods

Study design
The design of the international, open-label, phase 3 randomized IRIS trial has been reported previously. 16 Adult patients (aged 18-70 years) with previously untreated Ph þ CML-CP diagnosed within 6 months of study entry were eligible for the IRIS trial. Prior therapy with hydroxyurea or anagrelide was permitted.
Patients were randomized to receive treatment with imatinib 400 mg orally once daily or IFN administered subcutaneously at a daily dose of 5 million IU/m 2 of body surface area in combination with cytarabine at a daily dose of 20 mg/m 2 for 10 days every month. Stepwise dose escalation of imatinib to 400 mg twice daily was permitted if there were no dose-limiting adverse events (AEs) on imatinib 400 mg once daily and if any of the following criteria were met: failure to achieve a complete hematologic response (CHR) within 3 months; bone marrow contained more than 65% Ph þ metaphase cells at 12 months or loss of major cytogenetic response (MCyR). Patients in either arm were permitted to crossover to the alternate treatment group for any of the following reasons: lack of response (less than CHR by 6 months on therapy; no MCyR by 12 months on therapy); disease progression (increase in white blood cell count, 420 Â 10 9 /l); loss of CHR; loss of MCyR; treatment intolerance or, after study results had been released, reluctance to continue IFN plus cytarabine.
As per the protocol amendment in December 2005, planned patient assessments were reduced to include hematology evaluations every 6 months, cytogenetic bone marrow assessments annually and collection of study drug information as needed. If a patient discontinued study treatment, the reasons must have been documented. In addition, the routine collection of biochemistry evaluations, AEs and concomitant medication information has been discontinued; however, serious AE (SAE) reporting continues.
End points
The primary efficacy parameter of the IRIS trial was EFS, previously referred to as time to progression 16 or progressionfree survival. 17 An event was defined as loss of CHR or MCyR, progression to AP or BC, an increase in WBC count to 420 Â 10 9 /l or death from any cause during treatment. Secondary efficacy parameters included rate and duration of complete cytogenetic response (CCyR) and MCyR, the rate and duration of CHR, and OS. At least 20 metaphase cells were analyzed to determine CyR. Categorization of CCyR and CHR has been reported previously and remain unchanged. 16, 17 Major molecular response (MMR) was defined as BCR-ABL transcripts of p0.1% according to the international scale. 18 
Statistical analysis
The data cutoff date for this study of the ongoing IRIS trial was 31 January 2007. This date marked 6 years of follow-up after the last patient started imatinib therapy on this study. This study focuses on patients initially randomized to imatinib and does not include patients on the IFN and cytarabine arm due to the small number of patients still on the combination therapy arm (n ¼ 13, 2%). All 553 patients who were assigned to receive imatinib were followed for analysis of safety and efficacy until treatment discontinuation. Thereafter, patients were followed only for OS and hematopoietic stem cell transplant (HSCT) information until death, loss to follow-up or withdrawal of consent. Survival data were also collected on patients who underwent HSCT after discontinuing study treatment. Analyses of progression to CML-AP/BC, EFS and OS were performed using the Kaplan-Meier method according to the intention-to-treat principle, regardless of whether crossover occurred or not. Duration of response was censored at last assessment (or date of crossover) for patients without confirmed loss of response or progression to CML-AP/BC during first-line treatment.
Study conduct
This study was conducted in accordance with the Declaration of Helsinki and applicable regulatory requirements. The protocol was reviewed and approved by an appropriate institutional review board or ethics committee at each participating center. All patients gave written informed consent according to institutional guidelines prior to participation in this study.
Results
Patient disposition and treatment
A total of 1106 patients were enrolled in the study between June 2000 and January 2001. Most (65%) patients randomized to IFN plus cytarabine crossed over to the imatinib arm, whereas 3% of patients on the imatinib arm crossed over to the IFN plus cytarabine arm. Since the last published update, 17 no further patients have crossed over to the other treatment arm. Treatment intolerance was the most common reason cited for crossover to imatinib (26%), whereas four patients (o1%) crossed over to the IFN plus cytarabine arm due to intolerance.
In total, 364 of 553 (66%) patients randomized to imatinib were still receiving study treatment after 6 years of follow-up. Of the 359 patients discontinuing IFN/cytarabine and initiating treatment with imatinib on study, 239 (67%) remained on second-line imatinib at 6 years. Thus, 43% of IRIS patients originally randomized to IFN plus cytarabine were being treated with imatinib at 6 years. Since the last published report (data cutoff date January 2006), 18 (3%) patients randomized to imatinib discontinued study treatment (six patients discontinued due to lack of efficacy, one patient due to unconfirmed loss of CCyR and 11 patients for other reasons including withdrawal of consent or lost to follow-up). The median (mean±s.d., range) last dose given at the time of discontinuation of imatinib study treatment was 400 mg (467±179, 100-800 mg). The most common reasons for treatment discontinuation among all imatinib-treated patients were unsatisfactory therapeutic effect (12%), withdrawal of consent (6%) and AEs (4%) (but only 2% were considered related to study drug). Other reasons for study discontinuation included: stem cell transplantation (3%), protocol violation (3%), death (2%) and loss to follow-up (1%). Including the patients who crossed over to IFN plus cytarabine due to intolerance (1%) or lack of efficacy/progression (2%), a total of 5% of patients stopped imatinib study treatment due to side effects or AEs, and 14% stopped imatinib due to lack of efficacy or progression. Overall, 2% of patients discontinued imatinib therapy for reasons considered not related to imatinib therapy, including one case each of brain tumor, prostate cancer, small cell lung cancer, esophageal carcinoma, myelofibrosis, Steven-Johnson syndrome, thermal burn, fatigue and headache, car accident and influenza.
Among patients who received imatinib as initial therapy for CML, median duration of treatment was 70 months (range 0.2-78 months). Dose modifications were uncommon; the average daily dose over the 6-year period was 402 ± 56 mg for the 364 patients who remained on imatinib. The last reported daily dose of imatinib in this group was 400 mg in 83% of patients, and 300 mg in 7% of patients; a dose greater than 400 mg was reported for 10% of patients (600 mg (6%) and 800 mg (4%)).
In total, 60 patients discontinued while in CCyR. The average time since last cytogenetic analysis in these patients was 6.9 months (median 3.4 months). For at least half of these patients, these discontinuations may be due to the fact that imatinib became commercially available in 2001. Of the 71 patients who lost CCyR on study, 24 (34%) remained on study and regained CCyR (in 7 of these 24 patients, CCyR was regained after imatinib dose escalation) and 6 (8%) remained on study in MCyR.
Efficacy
Response and duration of response. Only 45 (8%) of the 534 (97%) patients who had achieved confirmed CHR, lost CHR during the study treatment. Another 24% of the patients who had achieved CHR had discontinued study treatment. Of the 490 (89%) patients who achieved an MCyR during treatment with imatinib, only 49 (10%) had documented loss of MCyR. Overall, 9% of these patients, as well as another 18% of the patients who had achieved an MCyR discontinued study treatment.
There were 456 (82%) patients on first-line imatinib who had achieved CCyR at any time during the study (two additional patients since the last update). Of these patients, 385 (84%) did not have documented loss of CCyR. A total of 325 (71%) were still on imatinib study drug, whereas 60 (13%) patients discontinued study treatment without having lost CCyR due to safety (n ¼ 22; 5%), unsatisfactory therapeutic effect (n ¼ 8; 2%) or for other reasons (n ¼ 30; 7%), including lost to follow-up, withdrawal of consent, HSCT or protocol violation. Of the 71 patients who lost CCyR, 24 (34%) remained on study and regained CCyR, 6 (8%) remained on study in MCyR and 41 (58%) discontinued study treatment. Thus, at the 6-year followup, 349 (63%) of all 553 randomized patients were in CCyR and remained on study treatment (Figure 1 ). The last bone marrow assessment for these patients was at a median of 5.5 years after start of study. Another 15 patients are still on study treatment (six in MCyR after they had lost CCyR and nine without documented MCyR).
Progression. Since the last update, 17 no patient had documented progression to CML-AP or CML-BC between years 5 and 6. The estimated rate of being free of progression to AP and BC at 6 years was 93% (95% confidence interval (CI) 91-95). Annual rates of progression to AP/BC were 1.5, 2.8, 1.6, 0.9, 0.5 and 0%, in years 1-6, respectively (Figure 2a) . The estimated annual event rate (loss of CHR, loss of MCyR, progression to AP/BC or death during treatment) was 3.3% in the first year, 7.5% in the second year, 4.8% in the third year, 1.5% in the fourth year, 0.8% in the fifth year and 0.4% in the sixth year (Figure 2a) . The estimated EFS was 83% (95% CI 80-86) at 6 years, with a total of 86 (16%) patients randomized to first-line imatinib experiencing an event during study treatment. Among the 456 patients who achieved CCyR, the estimated annual event rate was 5.4% in the first year, 2.3% in the second year, 1.1% in the third year and 0.3% in the fourth year after achieving that response (Figure 2b ). Annual rates of progression to AP/BC in this group were 2.1, 0.7, 0.3 and 0%, respectively (Figure 2b ). The estimated EFS at 6 years was 67.3% for patients in the high-risk Sokal group, 81.3% for intermediate-risk patients and 90.8% for low-risk patients (Po0.001). The estimated rate without progression to AP/BC was 82.8, 91.9 and 96.7%, respectively (P ¼ 0.002) and the OS at 6 years was 76.3, 86.9 and 93.9%, respectively (Po0.001).
Landmark analysis at 6 months. The landmark analysis excluded 7 (1%) patients who had an event before 6 months and 17 (3%) patients who discontinued imatinib for other reasons. The remaining 529 (96%) patients were divided by their cytogenetic response status at 6 months (within 4.5-7.5 months) based on evaluation of at least 20 metaphases: 19 (3%) patients had no CyR (495% Ph þ ), 39 (7%) patients had minor/minimal CyR (435-95% Ph þ ), 92 (17%) patients had partial cytogenetic response (PCyR) (40-35% Ph þ ) and 228 (41%) had CCyR (0% Ph þ ). Another 8 (1%) patients had CCyR at 3 months and PCyR at 6 months, they are all still on treatment. The remaining 143 (26%) patients had no evaluable assessment at 6 months. The EFS rate at 6 years was 59, 58, 85 and 91% for patients with no CyR, minimal/minor CyR, PCyR and CCyR, respectively (and 81% in those without assessment) (Figure 3a ). The estimated 6-year rates without progression to AP/BC were 80, 85, 94 and 97% in patients with no CyR, minor/minimal CyR, PCyR and CCyR, respectively, at 6 months (and 92% in those without assessment) (Figure 3b ). Of the patients with no CyR, minor/minimal CyR and PCyR, 42, 54 and 87% respectively, achieved a CCyR later during study. Of the eight patients without CyR who subsequently achieved CCyR, two had been previously dose escalated to 600 or 800 mg. Of the 19 patients without CyR at 6 months, 6 are still on imatinib study treatment.
Overall survival. Overall, 66 (12%) patients randomized to imatinib have died during study treatment or follow-up; 19 after HSCT, 20 due to reasons unrelated to CML and 27 (o5% of randomized patients) due to progression of CML. Of the 20 deaths unrelated to CML, 9 died due to secondary cancers, 6 died due to cardiac disease, 3 died due to sepsis or infections, 1 died due to Steven-Johnson syndrome and 1 died due to a car accident. Nine deaths occurred since the last update: three due to progression of CML, four after HSCT, one Figure 1 Patients on imatinib study treatment by year and best response achieved (CCyR vs no CCyR)
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A Hochhaus et al died due to septic shock and one due to urothelial carcinoma. 17 The estimated OS rate of patients randomized to imatinib was 88% at 6 years (95% CI 85-92). When data were censored at the time of HSCT and only CML-related deaths were considered, the estimated OS rate was 95% at 6 years (95% CI 92-97).
Adverse events
Safety data other than SAEs were not collected after July 2005. This report focuses on the SAEs reported between years 5 and 6. The most frequently reported SAEs were fever (n ¼ 6), vomiting (n ¼ 4), abdominal pain (n ¼ 3) and nausea (n ¼ 3). One case of vomiting and one case of abdominal pain were suspected to be related to imatinib treatment. The SAE profile after a median follow-up of 6 years was similar to that reported previously. 16, 17 Cardiac events. Kerkelä et al. 19 reported on a model suggesting the possibility of imatinib-related cardiac toxicity manifesting as congestive heart failure (CHF). In IRIS, drugrelated cardiac events were rare. In the most recent follow-up, only one cardiac event, a 23% reduction in the left ventricular ejection fraction, was reported and felt to be associated with imatinib treatment. The patient had a prior cardiac history, had undergone two aortic valve replacements and had switched to second-line imatinib following grade 3/4 dyspnea on IFN.
Secondary malignancy. There were four secondary malignancies reported between years 5 and 6 in the patients randomized to imatinib, three of which were not suspected to be related to study medication. In one patient, emergent appendiceal carcinoma was suspected to be related to imatinib therapy by the investigator. These IRIS data are integrated into the overall global safety database and monitored for the occurrence of secondary malignancies on a yearly basis.
Discussion
This update of the IRIS trial data after 6 years shows continued clinical benefit with 66% of patients with CML-CP remaining on study treatment and 63% being in CCyR with a continuing increase in the rate of MMR. The majority of responses were maintained and the annual risk of progression decreased over time. In fact, no new cases of disease progression were reported between years 5 and 6. In total, 82% of patients treated with imatinib achieved CCyR at any point during the study.
The 6-year OS rate of 88% for patients randomized to imatinib exceeds that reported for all other CML therapies. Even though the high rates of crossover (65%) precluded direct comparison of OS outcomes among patients randomized to firstline imatinib vs IFN plus cytarabine, the survival difference between the two arms at 6 years approached significance (88 vs 84%; P ¼ 0.075) in the intention-to-treat analysis, suggesting that first-line imatinib was superior to second-line imatinib, and patients should start imatinib as early as possible.
The level of CyR at 6 months was shown to be an important prognostic factor for freedom from progression, with 6-year EFS rates of 91% in patients achieving CCyR at that landmark vs 85% in those with PCyR and 58% in those with minor or minimal CyR. The EFS rate in the 3% of patients without any CyR (495% Ph þ ) at 6 months was 59% at 6 years. There is a continuing declining rate of progression events over time in patients who achieved CCyR. Among patients who achieved CCyR on imatinib, most events were observed in the first year after achievement of response, whereas none of the responders progressed to AP/BC after the third year after achievement of CCyR. These findings suggest that once a patient achieves a CCyR, the likelihood of a progression event declines over time with continued imatinib therapy. These data are consistent with another recent substudy of 53 imatinib-treated IRIS patients that showed that rates of CMR increased over time and, that after seven years on therapy, undetectable BCR-ABL was no longer a rare event. 20 In a subset of 53 patients with a median follow-up of 81 months, 52% of patients achieved undetectable BCR-ABL levels vs 7% at 36 months. Taken together, these findings suggest that patients with unfavorable characteristics progress Figure 3 (a) Event-free survival by level of cytogenetic response at 6 months after the initiation of imatinib treatment. At 72 months, the estimated rate of event-free survival was 91% in patients in complete cytogenetic response (CCyR), 85% in patients in PCyR, 58% in patients with minor or minimal cytogenetic response (CyR) and 59% in patients who failed to achieve CyR at 6 months. (b) Rates of patients without progression to accelerated phase (AP)/blast crisis (BC) by level of cytogenetic response at 6 months after the initiation of imatinib treatment. The 6-year rates without progression to AP/BC were 80% in patients with no CyR, 85% in patients in minor or minimal CyR, 94% in patients in partial cytogenetic response (PCyR) and 97% in patients in CCyR.
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A Hochhaus et al early on imatinib therapy, whereas those who respond well continue to show improved responses over time. Imatinib is well tolerated at a daily dose of 400 mg, with a consistent long-term safety profile. The majority of IRIS patients were treated with standard dose imatinib, with an average daily dose of 402 mg for patients who remained on imatinib at 6 years. With a median of 6 years follow-up, only 5% of patients have discontinued imatinib treatment due to side effects or AEs. Discontinuations considered related to imatinib therapy were reported in only 2% of the total population. Most grade 3/4 AEs occurred early in treatment and there was a decrease in incidence of these events with continued imatinib therapy after year 2. This makes sense in light of the fact that myelosuppression is the most common adverse effect of imatinib. 16 In untreated patients with CML, Ph þ stem cells are largely responsible for hematopoiesis. 21 Because imatinib effectively targets BCR-ABL, a degree of myelosuppression is expected in the early phases of treatment, before normal stem cells become predominant and normal hematopoiesis regenerates. 22 Since the 5-year analysis, routine reporting of AEs has been discontinued, with only SAE reporting ongoing. The most frequently reported SAEs in this analysis were fever, vomiting, abdominal pain and nausea, consistent with previous reports. 16, 17 One cardiac event possibly related to imatinib was reported. A possible correlation between imatinib and subsequent cardiac toxicity, specifically CHF, has been suggested based on animal models. 19 Two recent publications have addressed this concern in large numbers of patients. 23, 24 The first report by Atallah et al. 24 reviewed the records of 1276 patients who received imatinib on clinical trails at the MD Anderson Cancer Center. In total, 22 (1.7%) of these patients were identified as having symptoms that could be related to CHF, although only 8 (0.6%) of these were considered possibly or probably related to imatinib. The median age of these patients was 70 years with a median time to event from the start of imatinib of 162 days. Overall, 18 patients had previous medical conditions predisposing to CHF. Overall, 11 of the 22 patients required imatinib dose adjustments and interventions to manage the heart failure without further complications. The Novartis clinical database of registration trials consisting of 2327 patients has been examined for cardiac AEs. 25 Only 12 cases (0.5%) of CHF were identified. When related to imatinib exposure over the time period (5595 patient years), the incidence of CHF was 0.2%, consistent with the findings in other large series. CHF was therefore uncommon, occurring most often in patients with underlying cardiovascular risk factors. In a separate study of 103 patients with CML-CP, no cases of CHF or significant decrease in left ventricular ejection fraction were reported. 26 Further evidence of the low incidence of cardiac events was provided by CML Working Party of the Italian Group for Hematological Malignancies, which reported a 0.3% cardiac mortality rate for patients treated with imatinib. 27 A similar review has been performed in 972 patients with metastatic/inoperable gastrointestinal stromal tumor reported from an EORTC-ISG-AGITG study 62005 in which 7 patients were felt to have suffered a cardiac failure, including one death. 23 An in-depth analysis of these cases identified cardiac risk factors in each patient, leading the authors to conclude that imatinib does not induce cardiac left ventricular failure in inoperable gastrointestinal stromal tumor patients.
The rate of secondary malignancies of any type recorded in the imatinib global safety database was comparable to the overall rate of malignancy in an age-matched population. 28 In summary, with this 6-year analysis, imatinib showed continued clinical benefit as first-line therapy for newly diagnosed CML-CP. 29, 30 There were no cases of progression to AP or BC between the 5 and 6 year updates, OS was 88%, and EFS was 83%. There were no new safety issues. Thus, imatinib at a daily dose of 400 mg remains the standard of care for patients with newly diagnosed CML-CP.
